Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

One of the key characteristics is that unlike antibody-based HER2 drugs like Herceptin and Roche’s Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) it crosses the blood brain barrier ...

The latest Herceptin biosimilar is branded as Kanjinti (trastuzumab-anns) and is approved in all indications of the reference product. These are for the treatment of HER2-overexpressing adjuvant ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

Come Friday, it will be two years since Julie Zimmer rang the bell at the Mercy Health Springfield Cancer Center to celebrate ...

The Best of ASCO UAE Conference 2025, organised by SEHA, part of PureHealth Group, in collaboration with Tawam Hospital, ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.